Medical field organization secures $35 million in funding to progress its FieldForce platform
Field Medical, a pioneering company in the field of cardiac arrhythmia treatment, is making significant strides in the development of its next-generation pulsed field ablation (PFA) technology, with a particular focus on ventricular tachycardia (VT). The company's innovative FieldForce™ Ablation System, led by PFA pioneer Dr. Steven Mickelsen, combines cutting-edge catheter design with proprietary FieldBending™ energy for rapid and targeted ablation. This approach aims to improve efficiency and precision in treating challenging arrhythmias like VT.
Regulatory progress for Field Medical's technology has been noteworthy. In 2024, the company's technology received Breakthrough Device Designation and was selected for the FDA's TAP Pilot Program specifically for the VT indication, highlighting strong regulatory support for the system’s potential in treating ventricular arrhythmias.
The company recently closed an oversubscribed $35 million Series B financing round, reflecting investor confidence in the clinical promise and market potential of the FieldForce™ PFA platform. The funds will be utilised to initiate the pivotal VERITAS trial, advance the FieldForce Ablation System development, and expand Field Medical's clinical and regulatory capabilities.
Clinical evidence related to PFA technologies is expanding, with Boston Scientific receiving FDA approval in July 2025 for their FARAPULSE™ PFA System to treat persistent atrial fibrillation. However, Boston Scientific’s advances focus more on atrial fibrillation rather than ventricular tachycardia. Field Medical is positioning its technology as a next-generation solution targeting more complex arrhythmias such as VT, an area still underserved by current PFA devices.
The financing round was co-led by BioStar Capital and Cue Growth, with participation from existing strategic investors. Notable additions to Field Medical's Board of Directors include Mark Wisniewski, a seasoned executive with deep buy-side experience and M&A leadership, Marlou Janssen, a former President of Biotronik U.S. and VP/GM at EPD Solutions Philips, Alexei Mlodinow, an experienced medtech innovator with multiple exits, and Ben Cannon, a seasoned venture capital investor with deep experience scaling growth-stage companies.
Dr. Steven Mickelsen, founder and CEO of Field Medical, stated that their technology is poised to unlock an opportunity in the underpenetrated segment of ventricular tachycardia. With regulatory recognition, substantial funding, and a strong board, Field Medical is making meaningful progress toward addressing challenging ventricular arrhythmias with pulsed field ablation.
- Science and health-and-wellness come together in the innovative FieldForce Ablation System, developed by Field Medical, which focuses on improving cardiovascular health through the treatment of medical-conditions like ventricular tachycardia.
- Field Medical's significant breakthrough in pulsed field ablation (PFA) technology, backed by a $35 million Series B financing round, will enable the company to further invest in technology, finance, and clinical research, with the ultimate goal of treating challenging arrhythmias.
- The addition of experienced executives such as Mark Wisniewski, Marlou Janssen, Alexei Mlodinow, and Ben Cannon to Field Medical's Board of Directors, along with the company's recent FDA recognition, highlights the intersection of technology, finance, and health-and-wellness in advancing the fight against underpenetrated medical-conditions like ventricular tachycardia.
